JAN 12, 2016 08:00 AM PST
WEBINAR: Combined Use of Multiple Particle Characterization Technologies to Evaluate Targeted Liposomal Formulations: Implications for General Nanoparticle Development
SPONSORED BY: Beckman Coulter Life Sciences
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
11 31 6484

Speakers:
  • Professor, Cardiovascular Medicine, University of Texas Health Science Center at Houston
    Biography
      Dr. Klegerman received a B.A. in chemistry from the University of Illinois at Chicago in 1968 and a Ph.D. in biochemistry from Loyola University of Chicago in 1984. For more than 30 years, he has conducted biomedical research focusing on immunochemistry, immunoassay development, and conjugation chemistry. For the past 20 years, Dr. Klegerman has been involved in a collaborative effort with cardiovascular researchers under the direction of Dr. David D. McPherson to develop targeted immunoliposomes for diagnosis and treatment of cardiovascular diseases, joining the group when they moved to The University of Texas Health Science Center in Houston, where he now is a professor in the Division of Cardiovascular Diseases. As part of this effort, Dr. Klegerman founded two companies to develop the echogenic liposome technology into clinical products.

      He is an author of 75 scientific papers, awardee of four patents, and co-editor of a textbook of pharmaceutical biotechnology (1992).

    Abstract:
    January 12, 2016, 8:00am PT, 11:00am ET, 3:00pm GMT

    Targeted nanoparticle applications have become a major focus of translational development of both diagnostics and therapeutics for clinical use.  One of the oldest and best established nanoparticle formulations is liposomes, which can be readily targeted to tissue markers by chemical conjugation to ligands such as antibodies.  The cardiovascular research group at UTHealth has been exploring molecular targeting strategies for our intrinsically echogenic liposomes (ELIP) for nearly 25 years.  As part of this effort, we have developed evaluation methods for both conjugation and targeting efficiencies that rely on particle characterization techniques, especially the Beckman Coulter Multisizer.  This webinar will present the immunoblot assay (IBA) that measures IgG concentrations in the presence of liposomes.  We use the Multisizer to enumerate population based on size. We will present several sophisticated methods developed by us for determining targeting efficiency (TE), based on the CE and ELISA-measured antibody (Ab) binding affinity and binding efficiency.  The most informative measure of TE, however, is the specific TE, which is the product of the number of Ab molecules that actually bind to immobilized target molecules (determined by comparing the ELISA CE to the IBA CE) and the affinity.

    Learning Objectives:
    • Learn about the immunoblot assay (IBA) that measures immunoglobulin G (IgG) concentrations in the presence of liposomes.
    • Learn about sophisticated methods developed for determining targeting efficiency (TE), based on the CE and ELISA-measured antibody (Ab) binding affinity and binding efficiency 

    Show Resources
    Loading Comments...